- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03655262
Treating Phobia With Multivoxel Neuro-reinforcement
Specific phobias and other anxiety disorders represent a major mental health problem, and present a significant challenge to researchers because effective treatment usually involves repeated exposure to feared stimuli, and the high levels of associated distress can lead to termination of treatment. Recent advances in computational functional magnetic resonance imaging (fMRI) provide a method by which individuals may be unconsciously exposed to fearful stimuli, leading to effective fear reduction while eliminating a primary cause of attrition.
The objective of the current study is to use the novel approach of neuro-reinforcement based on decoded fMRI information to reduce fear responses to fearful stimuli (e.g., spiders, heights) in individuals with phobias, directly and unconsciously in the brain, without repeatedly exposing participants to their feared stimuli.
Participants will be randomized into one of three groups of varying neuro-reinforcement sessions (1, 3, or 5). They will complete tests of subjective fear and directed attention while being scanned by fMRI to measure engagement of amygdala activity to fearful stimuli as well as measured through other indicators of fear such as skin conductance response.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Anxiety disorders, the most common group of mental disorders in the United States, represent a major mental health problem. Phobias, in which fear and anxiety are triggered by a specific stimulus or situation, are the largest category of anxiety disorders and affect 5 - 12% of the world's population.
Exposure-based therapies are effective in reducing symptoms, but their effectiveness depends on the individual's capacity or willingness to consciously confront their feared object. The associated distress can be so extreme that it prevents patients from seeking treatment, and contributes to attrition from exposure once treatment begins. As a result, there is an unmet need for treatment that minimizes attrition and subjective patient discomfort.
The current study uses a novel technique of neuro-reinforcement based on decoded fMRI information to reduce fear responses to fearful stimuli directly and unconsciously without repeatedly exposing participants to those stimuli. The goals are to (1) confirm that our method decreases amygdala reactivity to images of phobic stimuli as well as (2) determine dosage-response optimization.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
California
-
Los Angeles, California, United States, 90095
- University of California, Los Angeles
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Individual has normal or corrected to normal vision
- Individual has normal or corrected to normal hearing
- Individual is competent to understand informed consent
Exclusion Criteria:
- Individual is unable to fill in consent form correctly
- Individual is unable to respond adequately to screening questions
- Individual is unable to maintain focus or to sit during assessment
- Individual has history of: neurological disease or defect (e.g., stroke, traumatic brain injury, schizophrenia or other psychological disorders, or seizures)
- Individual has vision problems (including cataracts, amblyopia, or glaucoma)
- Individual presents with: PTSD, Obsessive Compulsive Disorder, Substance Use Disorder, Current Major Depression, Bipolar Disorder, Psychosis, neurologic diagnoses or unstable serious medical conditions
- Individual does not present with more than one object of specific phobia
- Individual can touch the phobic object category during the pre¬treatment Behavioral Approach Test without presenting significant distress
- Individual is currently prescribed psychotropic medication
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1 Session
1 neuro-reinforcement session
|
Individuals will complete an implicit fmri neuro-reinforcement task where real-time brain activity is matched to a desired activation.
Individuals will also receive financial reward for activating the desired activation.
Visual feedback will be presented to indicate how well individuals' brain activity matches the desired activation.
Individuals will complete x day(s) of neuro-reinforcement.
|
Experimental: 3 Sessions
3 neuro-reinforcement sessions
|
Individuals will complete an implicit fmri neuro-reinforcement task where real-time brain activity is matched to a desired activation.
Individuals will also receive financial reward for activating the desired activation.
Visual feedback will be presented to indicate how well individuals' brain activity matches the desired activation.
Individuals will complete x day(s) of neuro-reinforcement.
|
Experimental: 5 sessions
5 neuro-reinforcement sessions
|
Individuals will complete an implicit fmri neuro-reinforcement task where real-time brain activity is matched to a desired activation.
Individuals will also receive financial reward for activating the desired activation.
Visual feedback will be presented to indicate how well individuals' brain activity matches the desired activation.
Individuals will complete x day(s) of neuro-reinforcement.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Subjective Fear Post-treatment Minus Pre-treatment
Time Frame: 10 days (measured at pre-treatment and post-treatment)
|
Subjective Fear Ratings of images of targeted phobic stimuli Minimum score of 0, Maximum score of 180, higher scores mean worse outcome. |
10 days (measured at pre-treatment and post-treatment)
|
Change in Amygdala Reactivity
Time Frame: 10 days (measured at pre-treatment and post-treatment)
|
The neural measure of difference in amygdala reactivity (measured by fMRI) to target phobic animals compared to control phobic animals from pre-treatment to post-treatment.
Lower numbers (i.e. more negative numbers) indicate greater amygdala decrease and and better outcomes.
|
10 days (measured at pre-treatment and post-treatment)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Skin Conductance Response: Physiological Arousal Post-treatment Minus Pre-treatment
Time Frame: 10 days (measured at pre-treatment and post-treatment)
|
Skin conductance to image presentation of targeted phobic stimuli post-treatment minus pre-treatment
|
10 days (measured at pre-treatment and post-treatment)
|
Fear Survey Schedule
Time Frame: 10 days (measured at pre-treatment and post-treatment)
|
Subjective fear ratings of a list of typical phobic stimuli Minimum score of 40, maximum of 200, higher scores mean worse outcome. |
10 days (measured at pre-treatment and post-treatment)
|
Stroop Task Post-treatment Minus Pre-treatment
Time Frame: 10 days (measured at pre-treatment and post-treatment)
|
Measure of preferential allocation of attentional resources measured in reaction time (seconds) for visual presentation of the targeted phobic stimulus
|
10 days (measured at pre-treatment and post-treatment)
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- R61MH113772 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Phobia
-
Umeå UniversityUppsala UniversityCompleted
-
Umeå UniversityCompleted
-
Stanford UniversityNational Institute of Mental Health (NIMH)CompletedSocial PhobiaUnited States
-
University of MinnesotaAstraZenecaCompletedSocial PhobiaUnited States
-
Modum BadCompleted
-
Johns Hopkins UniversityCompletedSpecific Phobia | Specific Phobia, Animal | Specific Phobia, Situational | Specific Phobia, Natural Environment | Childhood Anxiety DisorderUnited States
-
McMaster UniversityHamilton Health Sciences Corporation; Janssen-Ortho Inc., CanadaTerminated
-
Umeå UniversityCompleted
-
Milton S. Hershey Medical CenterNational Institute of Mental Health (NIMH)CompletedSocial PhobiaUnited States
Clinical Trials on Unconscious Neuro-reinforcement
-
Oticon MedicalCompleted
-
Oticon MedicalNot yet recruitingSensorineural Hearing Loss, Bilateral | Sensorineural Hearing Loss, Severe | Sensorineural Hearing Loss, Profound
-
University Hospital, ToulouseCompleted
-
Hospital Regional de Alta Especialidad del BajioCompleted
-
Societa Italiana di Chirurgia ColoRettaleUnknown
-
Karolinska InstitutetStockholm South General HospitalRecruiting
-
Centre for Addiction and Mental HealthRecruitingCognitive Impairment | Major Depressive Disorder | Cannabis UseCanada
-
Oticon MedicalCompletedDeafness | Hearing Loss, Sensorineural | Hearing Loss, CochlearCanada, Denmark
-
Clarkson UniversityRecruiting
-
Wayne State UniversityNational Institutes of Health (NIH)RecruitingFocal EpilepsyUnited States